Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed. In this international, multicenter trial, we randomly assigned 400 patients with severe symptomatic ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after ...

TCT 762: Long-Term Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Low and Intermediate Risk Patients: A Meta-Analysis of Randomized Controlled Trials Receive the the latest news ...

Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid regurgitation, according to a study published online Oct. 30 in the New England ...

For patients with symptomatic and severe or greater tricuspid regurgitation (TR), transcatheter tricuspid valve replacement (TTVR) plus optimal medical therapy (OMT) yields substantial improvement ...

"US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024" was originally created and ...

The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after implant, according to an update from the TRISCEND II trial. Among study ...

More wins occurred among patients in the valve-replacement group versus the control group with respect to death from any cause (14.8 versus 12.5 percent), postindex tricuspid-valve intervention (3 ...

Investigators saw more deaths in patients with severe TR after repeat mitral valve procedures; what to do about it is unclear ...

Press is the UCLA Principal Investigator. Recently, the FDA approved the first ever Transcatheter Tricuspid Valve Replacement (TTVR) device, Evoque. UCLA hopes to offer the Evoque system in the ...